NovaBridge Biosciences: income taxes paid, net
Income taxes paid, net for NovaBridge Biosciences. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All NovaBridge Biosciences financial histories
What this measure means
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
Exact concept: us-gaap:IncomeTaxesPaidNet. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Coverage by original unit
- CNY: 2021-01-01 to 2022-12-31. This unit’s selected history ends more than two years before capture.
- USD: 2022-01-01 to 2025-12-31.
These are separate reported series. A newer period in one unit does not update another unit’s history or establish a currency conversion.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2022-01-01 | 2022-12-31 | 697,000 | CNY | 2024-04-30 | 20-F · 0001104659-24-054452 |
| 2021-01-01 | 2021-12-31 | 9,077,000 | CNY | 2024-04-30 | 20-F · 0001104659-24-054452 |
| 2025-01-01 | 2025-12-31 | 0 | USD | 2026-04-07 | 20-F · 0001778016-26-000002 |
| 2024-01-01 | 2024-12-31 | 0 | USD | 2026-04-07 | 20-F · 0001778016-26-000002 |
| 2023-01-01 | 2023-12-31 | 0 | USD | 2026-04-07 | 20-F · 0001778016-26-000002 |
| 2022-01-01 | 2022-12-31 | 103,000 | USD | 2025-04-03 | 20-F · 0000950170-25-050344 |
Related financial histories
- NovaBridge Biosciences: total assets
- NovaBridge Biosciences: total liabilities
- NovaBridge Biosciences: stockholders equity
- NovaBridge Biosciences: cash and cash equivalents
- NovaBridge Biosciences: net income or loss
- NovaBridge Biosciences: operating cash flow
- NovaBridge Biosciences: capital expenditure payments
- NovaBridge Biosciences: revenue
- NovaBridge Biosciences: contract revenue excluding tax
- NovaBridge Biosciences: financing cash flow
- NovaBridge Biosciences: investing cash flow
- NovaBridge Biosciences: retained earnings or deficit
- NovaBridge Biosciences: basic weighted-average shares
- NovaBridge Biosciences: diluted weighted-average shares
- NovaBridge Biosciences: basic earnings per share
- NovaBridge Biosciences: diluted earnings per share
- NovaBridge Biosciences: income tax expense or benefit
- NovaBridge Biosciences: net property, plant and equipment
- NovaBridge Biosciences: share-based compensation expense
- NovaBridge Biosciences: operating income or loss
- NovaBridge Biosciences: current assets
- NovaBridge Biosciences: interest expense
- NovaBridge Biosciences: current liabilities
- NovaBridge Biosciences: goodwill carrying amount
- NovaBridge Biosciences: net finite-lived intangible assets
- NovaBridge Biosciences: net current accounts receivable
- NovaBridge Biosciences: operating expenses
- NovaBridge Biosciences: net inventory
- NovaBridge Biosciences: cost of revenue
- NovaBridge Biosciences: research and development expense
- NovaBridge Biosciences: common shares outstanding
- NovaBridge Biosciences: cash including restricted cash
- NovaBridge Biosciences: accumulated other comprehensive income or loss
- NovaBridge Biosciences: operating lease right-of-use asset
- NovaBridge Biosciences: operating lease liability
- NovaBridge Biosciences: gross property, plant and equipment
- NovaBridge Biosciences: accumulated depreciation on property, plant and equipment
- NovaBridge Biosciences: net intangible assets excluding goodwill
- NovaBridge Biosciences: other noncurrent assets
- NovaBridge Biosciences: other noncurrent liabilities
- NovaBridge Biosciences: prepaid expenses and other current assets
- NovaBridge Biosciences: current contract liabilities
- NovaBridge Biosciences: net deferred tax assets
- NovaBridge Biosciences: pre-tax income or loss from continuing operations
- NovaBridge Biosciences: profit or loss including noncontrolling interests
- NovaBridge Biosciences: comprehensive income or loss
- NovaBridge Biosciences: net income available to common stockholders
- NovaBridge Biosciences: general and administrative expense
- NovaBridge Biosciences: depreciation expense
- NovaBridge Biosciences: depreciation, depletion and amortization
- NovaBridge Biosciences: amortization of intangible assets
- NovaBridge Biosciences: other nonoperating income or expense
- NovaBridge Biosciences: interest paid, net
- NovaBridge Biosciences: operating lease payments
- NovaBridge Biosciences: change in accounts receivable
Inspect the source
- Entity
- NovaBridge Biosciences / CIK 0001778016
- Captured
- 2026-09-21T17:30:37.009Z
- SEC response SHA-256
919ae6d5c4d31cdabdd1b17e84729e161e7a34162bf41f2dc95f437b9c6abb04
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001778016.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))